Clinical Trial Update: Celecoxib in Treating Patients With Bladder Cancer [Phase 2, Phase 3]

View source ↗

Summary

Celecoxib is being studied in Phase 2 and Phase 3 trials for recurrent bladder cancer. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Celecoxib (Celecoxib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Bladder Cancer | Phase 2, Phase 3 | Status: COMPLETED